摘要
In September 2012,the US Chinese Anti-Cancer Association(USCACA) hosted two symposiums in Beijing.The USCACA hosted the first joint session at the 7th annual meetings of the Chinese Anti-Cancer Association(CACA),themed on "Collaboration between the US and China in Cancer Research." Six experts from the United States and China presented their latest work on basic and translational cancer research.During this symposium,5 young Chinese scholars,returnees after their training in the United States,were honored the"AFCR-USCACA Scholarships Award." The USCACA hosted a second symposium during the 15th annual meeting of the Chinese Society of Clinical Oncology(CSCO),focused on the "US-China Collaboration in Cancer Drug Clinical Development." An international delegation of oncology experts presented the innovative clinical trial strategies and discussed the biomarkers for cancer early detection and clinical trials,targeted therapy,and new drug development.The Oncology Drug Clinical Development and Safety Evaluation Committee was also launched to promote an innovative environment and to provide a collaborative platform for anti-cancer drug development in China.
In September 2012, the US Chinese Anti-Cancer Association （USCACA） hosted two symposiums in Beijing. The USCACA hosted the first joint session at the 7th annual meetings of the Chinese Anti-Cancer Association （CACA）, themed on ＂Collaboration between the US and China in Cancer Research.＂ Six experts from the United States and China presented their latest work on basic and translational cancer research. During this symposium, 5 young Chinese scholars, returnees after their training in the United States, were honored the ＂AFCR-USCACA Scholarships Award.＂ The USCACA hosted a second symposium during the 15th annual meeting of the Chinese Society of Clinical Oncology （CSCO）, focused on the ＂US-China Collaboration in Cancer Drug Clinical Development.＂ An international delegation of oncology experts presented the innovative clinical trial strategies and discussed the biomarkers for cancer early detection and clinical trials, targeted therapy, and new drug development. The Oncology Drug Clinical Development and Safety Evaluation Committee was also launched to promote an innovative environment and to provide a collaborative platform for anti-cancer drug development in China.
